NASDAQ · Medical - Diagnostics & Research

Aclaris Therapeutics, Inc. (ACRS) Stock

$3.83 +1.06% NASDAQ: ACRS Healthcare

Valuation

MetricValue
Price$3.83
Market Cap$534.91M
P/E Ratio-8.88
P/B Ratio5.90
P/S Ratio87.51
EPS (TTM)$-0.53
52-Week High$6.60
52-Week Low$1.74
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-61.65%
ROA-42.15%
ROCE-56.99%
Gross Margin-950.00%
Operating Margin-950.00%
Net Margin-921.50%
Debt/Equity0.02
Current Ratio5.21

Annual Financials (USD)

Metric20212022202320242025
Revenue$7.0M$30.0M$31.0M$19.0M$8.0M
Operating Profit$-90.0M$-90.0M$-97.0M$-142.0M$-76.0M
Net Profit$-91.0M$-87.0M$-88.0M$-132.0M$-65.0M
EPS$-1.60$-1.33$-1.27$-1.71$-0.53
Op Margin-1327.1%-302.0%-311.6%-758.2%-975.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$251.0M$255.0M$197.0M$220.0M$160.0M
Total Liabilities$54.0M$57.0M$40.0M$65.0M$57.0M
Cash$27.0M$45.0M$40.0M$25.0M$20.0M
Borrowings$1.0M$1.0M$0$0$2.0M

Latest News

Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength? Zacks · Jul 1, 2026 3 Penny Stocks Under $5 Backed by Real Revenue Growth MarketBeat · Jun 20, 2026 Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On Insider Monkey · Jun 7, 2026 Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052 MarketBeat · Jun 4, 2026 Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference GlobeNewswire · May 28, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-52.0M$-68.0M$-78.0M$-20.0M$-47.0M
Investing Cash Flow$-168.0M$12.0M$45.0M$-70.0M$48.0M
Financing Cash Flow$-2.0M$0$0$0$-6.0M
Net Cash Flow$5.0M$18.0M$-5.0M$-15.0M$-5.0M
Free Cash Flow$-52.0M$-68.0M$-80.0M$-20.0M$-47.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.19
EV / EBITDA-9.32
FCF Yield-8.64%
Quick Ratio3.46
Interest Coverage0.00
Return 1Y226.19%
Return 3Y-44.37%
Return 5Y-64.09%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AGMBAgomAb Therapeutics NV - ADRs representing one common share. $9.08 -1.52% -10.26 $447.17M 0.00%
ALDXAldeyra Therapeutics, Inc. $0.92 -3.31% -3.02 $55.27M 0.00%
ALMSAlumis Inc. $7.16 +2.73% -1.80 $883.77M 0.00%
ANABAnaptysBio, Inc. $45.95 -0.56% 7.19 $1.36B 0.00%
ATTOAttovia Therapeutics, Inc. $16.21 -0.61% -23.81 $697.52M 0.00%

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is led by CEO Neal S. Walker, employs 61 people, headquartered in US, publicly traded since 2015.

Aclaris Therapeutics, Inc. (ACRS) stock trades at $3.83 with a market capitalization of $534.91M. The stock is valued at a price-to-earnings (P/E) ratio of -8.88, price-to-book of 5.90, price-to-sales of 87.51. Over the past 52 weeks the stock has ranged between $1.74 and $6.60, and currently trades 42.0% below its 52-week high.

On profitability, Aclaris Therapeutics, Inc. generates a return on equity (ROE) of -61.65%, return on capital employed of -56.99%, an operating margin of -950.00%, a net profit margin of -921.50%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides